Table 1 The clinical data and imaging findings of patients
Characteristic | glial cell hyperplasia | low grade glioma | χ2/z | p |
|---|---|---|---|---|
n | 41 | 87 | Â | Â |
Gender, n (%) | Â | Â | 0.040 | 0.841 |
Male | 26 (63.4%) | 52 (59.8%) | Â | Â |
Female | 15 (36.6%) | 35 (40.2%) | Â | Â |
Clinical symptoms, n (%) | Â | Â | Â | 1.000 |
Absent | 3 (7.3%) | 6 (6.9%) | Â | Â |
Present | 38 (92.7%) | 81 (93.1%) | Â | Â |
Tumor shape, n (%) | Â | Â | 0.114 | 0.735 |
Irregular | 19 (46.3%) | 36 (41.4%) | Â | Â |
Regular | 22 (53.7%) | 51 (58.6%) | Â | Â |
Mass effect, n (%) |  |  | 15.240 | < 0.001 |
Absent | 29 (70.7%) | 28 (32.2%) | Â | Â |
Present | 12 (29.3%) | 59 (67.8%) | Â | Â |
Cystic degeneration, n (%) | Â | Â | 4.473 | 0.034 |
Absent | 33 (80.5%) | 52 (59.8%) | Â | Â |
Present | 8 (19.5%) | 35 (40.2%) | Â | Â |
Hemorrhage, n (%) | Â | Â | Â | 0.241 |
Absent | 34 (82.9%) | 79 (90.8%) | Â | Â |
Present | 7 (17.1%) | 8 (9.2%) | Â | Â |
Necrosis, n (%) | Â | Â | 2.526 | 0.112 |
Absent | 36 (87.8%) | 64 (73.6%) | Â | Â |
Present | 5 (12.2%) | 23 (26.4%) | Â | Â |
Garland pattern enhancement, n (%) | Â | Â | 4.944 | 0.026 |
Absent | 30 (73.2%) | 44 (50.6%) | Â | Â |
Present | 11 (26.8%) | 43 (49.4%) | Â | Â |
Edema, n (%) | Â | Â | 0.203 | 0.652 |
Absent | 18 (43.9%) | 33 (37.9%) | Â | Â |
Present | 23 (56.1%) | 54 (62.1%) | Â | Â |
Age, median (IQR) | 51 (35, 63) | 57 (42, 66) | -1.201 | 0.231 |
Maximum tumor diameter, median (IQR) | 26 (18, 35) | 34 (25.5, 45) | -3.191 | 0.001 |